15 research outputs found

    ADHERENCIA TERAPÉUTICA Y ABUSO DE TRATAMIENTO DE ALIVIO SINTOMÁTICO EN PACIENTES CON AGUDIZACIÓN DE ASMA BRONQUIAL

    Get PDF
    INTRODUCCIÓNClásicamente el tratamiento del asma se basa en distintos fármacos utilizados como tratamiento de mantenimiento y a demanda. En los últimos años sigue en debate la opción de utilizar un solo dispositivo de inhalación con formoterol/GCI para ambas modalidades ya que se ha comprobado que disminuye las consecuencias de la baja adherencia terapéutica y del abuso del tratamiento de rescate, que se han relacionado en múltiples ocasiones con un mayor riesgo de sufrir exacerbaciones. MATERIAL Y MÉTODOSSe trata de un estudio descriptivo transversal en el que se ha incluido a todo paciente acudido al Servicio de Urgencias del HCU Lozano Blesa por una exacerbación asmática durante el periodo del 1/12/2021 al 31/1/2022 obteniendo un tamaño muestral final de 40 pacientes. Se han recogido las siguientes variables: edad, sexo, número de exacerbaciones asmáticas en el último año divididas en leves y graves, tratamiento de rescate utilizado (SABA vs Formoterol/GCI), número de dispensaciones farmacéuticas de éste, abuso del tratamiento de rescate y adherencia terapéuticaRESULTADOSUn 55% de los pacientes estudiados utilizaban SABA como tratamiento de rescate, mientras que un 45% utilizaban formoterol/GCI. Un 72,5% eran mujeres y la edad media era de 47,42 años. Se registraron 60 exacerbaciones en total, un 65% de ellas graves con una media de 1,5 exacerbaciones por paciente. Un 35% no presentó ninguna exacerbación. De los pacientes con SABA, un 36,4% cumplían criterios de abuso. De aquellos con formoterol/GCI un 83,3% lo hacía de mala adherencia terapéutica. No se encontraron diferencias en el número de exacerbaciones entre los pacientes con SABA y aquellos con formoterol/GCI. Sólo se ha encontrado una relación levemente significativa (p=0,046) entre el abuso de SABA y el número de exacerbaciones. CONCLUSIÓNEl abuso de SABA se ha relacionado con un incremento de las exacerbaciones por mal control de la enfermedad. Son necesarios más estudios que corroboren el papel de las combinaciones de LABA/GCI como tratamiento de rescate en los primeros escalones terapéuticos del asma bronquial<br /

    Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)

    Get PDF
    Objectives: The objective of this study was to estimate the association between tocilizumab or corticosteroids and the risk of intubation or death in patients with coronavirus disease 19 (COVID-19) with a hyperinflammatory state according to clinical and laboratory parameters. Methods: A cohort study was performed in 60 Spanish hospitals including 778 patients with COVID-19 and clinical and laboratory data indicative of a hyperinflammatory state. Treatment was mainly with tocilizumab, an intermediate-high dose of corticosteroids (IHDC), a pulse dose of corticosteroids (PDC), combination therapy, or no treatment. Primary outcome was intubation or death; follow-up was 21 days. Propensity score-adjusted estimations using Cox regression (logistic regression if needed) were calculated. Propensity scores were used as confounders, matching variables and for the inverse probability of treatment weights (IPTWs). Results: In all, 88, 117, 78 and 151 patients treated with tocilizumab, IHDC, PDC, and combination therapy, respectively, were compared with 344 untreated patients. The primary endpoint occurred in 10 (11.4%), 27 (23.1%), 12 (15.4%), 40 (25.6%) and 69 (21.1%), respectively. The IPTW-based hazard ratios (odds ratio for combination therapy) for the primary endpoint were 0.32 (95%CI 0.22-0.47; p < 0.001) for tocilizumab, 0.82 (0.71-1.30; p 0.82) for IHDC, 0.61 (0.43-0.86; p 0.006) for PDC, and 1.17 (0.86-1.58; p 0.30) for combination therapy. Other applications of the propensity score provided similar results, but were not significant for PDC. Tocilizumab was also associated with lower hazard of death alone in IPTW analysis (0.07; 0.02-0.17; p < 0.001). Conclusions: Tocilizumab might be useful in COVID-19 patients with a hyperinflammatory state and should be prioritized for randomized trials in this situatio

    Çédille, revista de estudios franceses

    Get PDF
    Presentació

    COMPORTAMENTO RUMINAL DE TOURINHOS ALIMENTADOS COM DIETAS DE GRAMÍNEA E CONCENTRADO COMERCIAL SUPLEMENTADAS COM HIBISCO E SACARINA

    Get PDF
    Aiming at evaluating hibiscus (Hibiscus rosa-sinensis) and sacarina as supplements for young bulls, four crossbred animalswere displayed in a Latin square experimental design. The following treatments were performed: 1 – 75% pasture + 25% concentrate; 2 – 50% pasture + 25% concentrate + 25% hibiscus; 3 – 50% pasture + 25% concentrate + 25% sacarina; and 4 – 25% pasture + 25% concentrate + 25% hibiscus + 25% sacarina. Diet composition, rumen fermentation, DM and CP degradation rates were evaluated. Rumen pH values varied from 5.82 to 6.98, for diets supplemented with hibiscus, at 9h post-feeding, and with sacarina, at the feeding moment. Ammonia N contents did not present great changes when only hibiscus or sacarina were added to the diet, but there was a significant effect when both were added P<0.001). Rumen SCFA concentrations were lower due to saccharine presence in the diet (P<0.01). Sacarina diet presented higher values for readily soluble fraction for DM and CP (P<0.01). Sacarina promoted a higher effect on DM degradation of total diets (P<0.05). Hibiscus and sacarina inclusion increased the degradation of diets for grazing young bulls (P<0.05). Including these feed to the concentrate, the rumen environment and functionality were improved. Thus, it is viable the partial replacement of concentrate by the tested feed

    Morphological, structural, and magnetic properties of Co nanoparticles in a silicon oxide matrix

    No full text
    We present a morphological, structural, and magnetic characterization of Co nanoparticles (mean diameter of 10.3 ± 1.8 nm) grown using a gas aggregation source and embedded in a silicon oxide matrix by sequential deposition of nanoparticles and silicon oxide. We show that the Co nanoparticles >soft-land> on the substrates and suffer a moderate oxidation in contact with the silicon oxide. Despite this moderate oxidation, it is found that, at room temperature, the magnetic volume of the resulting nanoparticles is below the superparamagnetic limit. The results presented in this article are compatible with the presence of an assembly of magnetically independent particles that also display a moderate exchange bias at low temperature. © 2011 Springer Science+Business Media B.V.This study was supported by the Spanish Ministerio de Ciencia e Innovación under projects MAT2005-05524-C02-02, MAT-2007-66181, MAT2008-06765-C02, MAT2008-06517-C02-01, CSD2007-00041 (NANOSELECT), CSD2008-00023 (FUNCOAT), CSD2009-00013, and the European Commission NMP3-SL-2008-214107. Consejo Superior de Investigaciones Científicas and the Spanish Ministerio de Ciencia e Innovación are thanked for financial support. Jordi Llobet from the Instituto de Microelectrónica de Barcelona IMB-CNM-CSIC and Xavier Borrisé from the Centro de Investigación en Nanociencia y Nanotecnología, Bellaterra, Barcelona, CIN2-CSIC are thanked for the preparation of the cross-sectional samples. TEM study has been carried out at the LABMET, Red de Laboratorios de la Comunidad de Madrid. http://dx.doi.org/10.1007/s11051-011-0518-5Peer Reviewe

    Compilación de Proyectos de Investigación desde el año 2003 al 2012

    No full text
    Listado de Proyectos de investigación de UPIICSA desde 2003 a 201

    En marcha con las TIC : experiencias con las tecnologías educativas en Extremadura

    No full text
    Se recopilan aportaciones y experiencias de profesionales de la educación extremeños que han empleado programas y herramientas para crear materiales que sirvan para su trabajo en el aula y para promocionar el aprendizaje a través del uso del ordenador.ExtremaduraConsejería de Educación. Dirección General de Política Educativa; Calle Delgado Valencia, 6; 06800 Mérida (Badajoz); +34924006714; +34924006716; [email protected]
    corecore